Every middle-market CRE sponsor faces the same question on every deal: can I fill this raise from my own LP base?
If the answer is yes, you raise on your terms. Your promote structure, your fee schedule, your co-investment percentage, your deal selection freedom. You choose the deal. You set the waterfall. Your LPs invest because they trust you.
If the answer is no, the deal becomes a joint venture. An institutional partner comes in, and the economics of the entire capital stack change. Not just the piece the institution funds. The whole deal.
Most sponsors know which side of that line they'd rather be on. What most haven't done is calculate the dollar-level difference between the two outcomes on the same deal.
Two Raises, One Deal
Take a $40M multifamily value-add acquisition. 65/35 leverage. $14M in total equity. 8% compounded preferred return. Five-year hold. 2.0x exit.
Raise A: You fill it from your LP base. Individual HNW LPs, $100K-$200K each, plus your co-invest at 3% of total equity. You set the terms: 75/25 promote to a 15% IRR hurdle, 50/50 above that. 1.5% acquisition fee. 2.5% annual asset management fee. No deal selection constraints. No clawback. Full freedom.
On this deal, the GP nets roughly $4M.
Raise B: You can't fill it, so you bring in an institutional JV partner. The institution takes the majority of the equity. Your existing LPs get a small allocation or none at all. The terms reset to what the institution dictates: promote compressed to 85/15 below a 12% hurdle, 70/30 above it. Co-invest increases to 10% of total equity. Acquisition fee drops to 1%. Asset management fee drops to 1%. Committed capital fee prohibited. Clawback required. And the institution has approval rights over which deals you can pursue.
On the same deal, same exit, the GP nets roughly $3.4M.
That's roughly $600K less in GP profit. The dollar difference alone understates what actually changed. In Raise A, the GP committed $420K in co-investment and retained full control. In Raise B, the GP committed $1.4M - more than three times as much - and gave up control of deal selection, fee structure, and the LP relationship.
On a $40M deal, the GP surrenders $1.0M in revenue to avoid $407K in LP acquisition cost.
Run your own numbers →The Compounding Problem
The economic gap between these two outcomes extends beyond one deal.
When you raise from individual HNW LPs and the deal performs, those LPs come back. The first distribution validates the trust they placed in you. They re-invest in the next deal, often at higher amounts. Some refer colleagues. Your LP base grows, and the cost to raise capital from that growing base drops with every deal.
Institutional capital doesn't compound. It's one deal, one check. The next deal starts from zero with a new institution, a new negotiation, and a new set of compressed terms.
Over three deals, the difference between these two paths isn't $600K. It's north of $2M in cumulative GP profit, with nearly $3M less GP capital tied up across the portfolio.
What Determines Which Side You're On
The threshold between Raise A and Raise B isn't deal quality. It isn't track record. It isn't market conditions. Sponsors on both sides of the line are doing good deals in good markets with solid execution.
The threshold is the size and depth of your individual LP base.
A sponsor with enough committed HNW LPs can fill a $14M raise. A sponsor without enough can't. The difference between those two positions - between keeping your economics and handing them to an institution - can come down to a handful of LPs.
Most middle-market sponsors built their LP base the same way: friends, family, professional contacts, referrals from existing LPs, conference introductions. This works. It's how most firms get their first several deals done. It also has a ceiling, and the ceiling is the size of the GP's personal network.
When the deals get larger, or the raise timeline gets tighter, or a few reliable LPs don't re-up, the network isn't enough. The sponsor hits the threshold, and the deal tips from Raise A to Raise B. Not because the deal changed, but because the LP base couldn't keep pace with the capital requirement.
The Gap No One Measures
There are roughly 22 million accredited investor households in the United States. Fewer than 5% have any direct exposure to private equity real estate. The pool of potential individual LPs for a well-run middle-market CRE sponsor is enormous. The problem isn't supply. It's access.
Most sponsors have no systematic way to reach HNW individuals beyond their personal network. No infrastructure for finding them, engaging them, building trust at scale, and converting that trust into committed capital over time. The network is the only channel, and when the network maxes out, the sponsor's options collapse to institutional JV or broker - both of which come at a significant cost to GP economics and firm autonomy.
This is the gap that determines which side of the line a sponsor lands on. Not deal quality. Not market timing. The gap between the capital they need and the number of individual LPs they can reach.
Some sponsors have started closing that gap. They've built systematic approaches to HNW LP acquisition - using educational content, data-driven targeting, and relationship infrastructure - to grow their LP base beyond personal networks. The economics of this approach typically start at 5-6% cost-of-capital in year one, dropping toward 2-3% by year three as repeat LPs and referrals compound the base. That front-end cost is a fraction of what sponsors give up in a single JV deal.
The first step isn't building a platform. It's recognizing the threshold for what it is: the single biggest determinant of your GP economics on every deal you do. If you can fill the raise, you keep everything. If you can't, you give up far more than most sponsors have calculated.
The question worth answering isn't what your capital costs. It's what it costs you every time you fall short.
This is general educational information and does not constitute investment, legal, or tax advice. The worked example uses simplified assumptions (compounded 8% pref, lump-sum exit, no interim distributions) to illustrate directional economics. Actual deal terms, GP economics, and cost-of-capital vary by firm, deal structure, and market conditions. Carried interest tax treatment per IRC Section 1061 as preserved by the One Big Beautiful Bill Act (July 2025).